Business Context and Reporting Period
Company: InflaRx N.V.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of May 2024 (Filing Date: May 8, 2024)
Principal Executive Office: Winzerlaer Str. 2, 07745 Jena, Germany
This filing serves to incorporate by reference the company's Unaudited Condensed Consolidated Financial Statements and Management's Discussion and Analysis (MD&A) for the three months ended March 31, 2024, as well as a press release dated May 8, 2024.
Key Financial Metrics
The provided text contains only the cover page and exhibit index of the Form 6-K. It does not include the actual financial statements or MD&A content.
- Revenue: Not provided in this text.
- Profit/Loss: Not provided in this text.
- Cash Flow: Not provided in this text.
- Margins: Not provided in this text.
- Debt and Liquidity: Not provided in this text.
Note: Specific financial values are located in Exhibit 99.1 and Exhibit 99.2, which are referenced but not included in the input content.
Material Changes
The filing text does not provide specific data to compare current period performance against prior periods. Material changes would be detailed in the referenced MD&A (Exhibit 99.2).
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.3) dated May 8, 2024, which likely contains management commentary, but the content of the release is not included in the input text.
Risks and Contingencies: No specific risks or contingencies are detailed in the cover page text. These are typically found in the MD&A or the press release.
Investor Verification Checklist
- Review Exhibit 99.1 for the full Unaudited Condensed Consolidated Financial Statements for the three months ended March 31, 2024.
- Read Exhibit 99.2 (MD&A) to understand the reasons behind financial results and material changes.
- Examine Exhibit 99.3 (Press Release) for the latest operational updates, clinical trial data, or strategic announcements made on May 8, 2024.
- Verify the incorporation by reference status of these exhibits into the company's Form S-8 and Form F-3 registration statements.